Shanghai, China – 5 March, 2015 - Shanghai MicroPort Orthopedics Co ("MicroPort Orthopedics Shanghai"), a subsidiary of Shanghai MicroPort Medical (Group) Co ("MicroPort"), recently gained the registration certificate from China Food and Drug Administration ("CFDA") for its in-house-developed Futago™ Lumbar & Thoracic Fusion Device ("Futago™"). Futago™ received CE Mark approval in 2011.
Futago™ is consisted of a fusion device and a mark. The fusion device is made of Polyetheretherketone ("PEEK") and the mark is made of titanium alloy. Futago™ is implanted in posterior approach, compatible with Spinal Posterior Fixation System, and indicated for lumbar or thoracic interbody fusion, including degenerative discopathy, lumbar pseudarthrosis and degenerative or isthmic with grade 1 residual displacement after reduction. Futago™ features patented teeth design, biocompatible PEEK material, secure implant placement, optimum graft area for bone ingrowth and special anatomic design which makes the implant easy to insert.
MicroPort Orthopedics Shanghai started to design and develop Futago™ in 2009. The first clinical implantation of Futago™ was completed in July 2010, in which a total of 70 patients were implanted the device and the fusion rate achieved 100%, proving its safety and efficacy.
This website may store cookies on your browser. Cookies are mostly used to make the website work as you expect it to. No cookie will directly identify you, but it can give you a more personalized browsing experience.
MicroPort respects your privacy rights, so you can block some types of cookies. Technically non-essential cookies and tracking mechanisms, that enable us to provide you with customized offers (marketing cookies), are only used if you have given prior consent to such use.
By clicking “Save”, only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings.